December 13, 2024

Large Study Reveals Melanoma's Hidden Risks

Analysis of over 280,000 melanoma patients reveals these survivors face significantly elevated risks of developing 12 different types of second primary cancers, with the risk being particularly pronounced in younger patients and those with thicker tumors.

Conexiant

December 12, 2024

Melanoma Recurrence Signs with ATLAS Guide

Study published in the Journal of the American Academy of Dermatology explores key symptoms and detection strategies for melanoma recurrence, providing potential improvements for surveillance protocols.

Conexiant

December 09, 2024

UV Radiation, Virus Key Drivers of Merkel Cell Carcinoma Cases

A recent study in JAMA Dermatology reveals that over 65% of Merkel cell carcinoma cases in the US may be attributed to ultraviolet radiation exposure, while 63.8% may be linked to the Merkel cell polyomavirus.

Conexiant

December 09, 2024

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monoth...

The ASCO Post

November 26, 2024

Do Cancer Drugs Trigger Skin Issues?

A recent analysis reveals that nearly 50% of significant dermatologic adverse events linked to anticancer therapies are associated with targeted therapies, with rash, dry skin, and alopecia being the most commonly reported adverse events.

Conexiant

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

April 30, 2024

Study Explores Impact of Cannabis Extract on Melanoma Cells

The cannabis extract cannabinoid PHEC-66 may effectively treat melanoma.

Conexiant

April 30, 2024

Model for Predicting Survival Following SLNB in Melanoma

Researchers have developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.

Conexiant

April 29, 2024

Adjuvant mRNA-Based Personalized Therapy Plus Immunotherapy in High-Risk Resected Melanoma

The addition of a novel mRNA-based individualized neoantigen therapy to pembrolizumab may improve recurrence-free survival in patients with completely resected high-risk cutaneous melanoma.

Conexiant